Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

Next Previous
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tebapivat (Primary)
  • Indications Beta-thalassaemia; Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors Agios Pharmaceuticals

Most Recent Events

  • 31 Jul 2025 According to Agios Pharmaceuticals media release, the first patient has been dosed in the Phase 2 trial investigating tebapivat in sickle cell disease and the trial is enrolling across three dose cohorts (2.5mg, 5mg, 7.5mg).
  • 22 May 2025 Status changed from not yet recruiting to recruiting.
  • 20 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top